SPARC

PROSEEK, one of the largest phase-2 studies in early Parkinson's disease, encompassed 84 sites across the United States, Europe, and India

The stock of SBI Card has witnessed a decent correction from the peak of 1139 levels and has bottomed out near 920 levels

The chart looks attractive for further upside movement in SPARC with the RSI indicator also showing a trend reversal

It's revenue from operations for the quarter under review came in at Rs 185.45 crore, clocking a growth of 970.73 per cent YoY from Rs17.32 crore reported in Q1FY20

The company has received a Complete Response Letter (CRL) from the USFDA for the new drug application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension).

In August this year, Abraxis Biosciences LLC had alleged that SPARC's filing of NDA or Taclantis injection is an act of infringement of the Orange Book listed patents for Abraxane.

Shares of SPARC were trading at Rs 146.7 apiece, up 2.34% on the BSE

The stock dipped 15% to Rs 332 on BSE in early morning trade on back of heavy volumes

The company is contesting the demand, which is for the assessment year 2013-14